(Note: For PDF File Swipe To The End Of Article)
Introduction: What Is Leukemia?
Leukemia is a type of cancer that develops in blood-forming tissues, particularly the bone marrow, where blood cells are produced. It usually involves abnormal growth and accumulation of white blood cells or their immature precursors. These abnormal cells interfere with the production and function of healthy blood cells, potentially affecting the body's ability to fight infections, transport oxygen, and prevent excessive bleeding.
Blood is essential for maintaining life. It transports oxygen and nutrients, removes waste products, protects the body against infections, and helps control bleeding after an injury. These functions depend on the coordinated activity of red blood cells, white blood cells, platelets, and plasma.
In a healthy person, the bone marrow continuously produces new blood cells according to the body's needs. These cells develop through a carefully regulated process known as hematopoiesis. In leukemia, genetic changes in certain blood-forming cells disrupt normal growth and maturation. The affected cells may multiply uncontrollably, survive longer than they should, or fail to mature into fully functional blood cells.
As leukemia progresses, abnormal cells can accumulate in the bone marrow and sometimes circulate in the bloodstream or infiltrate organs such as the spleen, liver, lymph nodes, skin, and central nervous system. The resulting effects depend on the type of leukemia, the speed at which it develops, and the extent of disease.
Leukemia is not a single disease. It includes several distinct cancers that differ in their biological characteristics, clinical presentation, treatment requirements, and prognosis. The four major categories are acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, and chronic myeloid leukemia.
Acute leukemias generally progress rapidly and require prompt treatment. Chronic leukemias often develop more gradually, and some patients may initially have no symptoms. However, the distinction between acute and chronic leukemia is not simply a measure of how ill someone feels; it reflects important biological differences in the cancer cells.
Although a leukemia diagnosis can be frightening, advances in hematology, molecular testing, targeted therapy, immunotherapy, and stem cell transplantation have improved treatment options and outcomes for many patients.
Some forms of leukemia can be cured in a substantial proportion of patients, particularly certain childhood leukemias and acute promyelocytic leukemia. Other forms can often be controlled for many years with modern treatment. Outcomes vary considerably according to the leukemia subtype, genetic findings, age, overall health, and response to therapy.
Understanding leukemia is essential for recognizing warning signs, obtaining an accurate diagnosis, selecting appropriate treatment, and supporting patients throughout their care.
1. Understanding the Blood and Bone Marrow
To understand leukemia, it is important to understand how normal blood cells are produced.
Blood contains several major components, each performing a different function.
Red Blood Cells
Red blood cells, also called erythrocytes, transport oxygen from the lungs to tissues throughout the body.
They contain hemoglobin, an iron-containing protein that binds oxygen. Red blood cells also help transport some carbon dioxide back toward the lungs.
When red blood cell production decreases, a person may develop anemia. Anemia can cause fatigue, weakness, pale skin, dizziness, shortness of breath, and a rapid heartbeat.
In leukemia, anemia may develop because abnormal cells occupy the bone marrow and interfere with normal red blood cell production.
White Blood Cells
White blood cells, or leukocytes, help protect the body against infections and participate in immune responses.
They include several types:
- Neutrophils, which are particularly important for fighting many bacterial and fungal infections.
- Lymphocytes, which include B cells, T cells, and natural killer cells.
- Monocytes, which can develop into macrophages and other cells involved in immune defense.
- Eosinophils and basophils, which participate in particular immune and inflammatory responses.
The number of white blood cells in a patient with leukemia may be high, normal, or low.
A high white blood cell count does not necessarily mean that the immune system is functioning effectively. Leukemia cells may be abnormal and unable to provide normal protection against infection.
Even when the total white blood cell count is elevated, the patient may have too few healthy, functional neutrophils.
Platelets
Platelets are small blood components that help form clots and stop bleeding.
They gather at injured blood vessels and participate in the formation of a platelet plug. Additional clotting proteins then help stabilize the clot.
A low platelet count, known as thrombocytopenia, can cause easy bruising, nosebleeds, gum bleeding, pinpoint red or purple spots on the skin, and prolonged bleeding after minor injuries.
Leukemia can reduce platelet production by interfering with normal bone marrow function.
Bone Marrow
Bone marrow is the soft tissue found inside certain bones, including the pelvis, sternum, ribs, and vertebrae.
It contains hematopoietic stem cells, which can develop into all the major types of blood cells.
These stem cells give rise to different developmental lineages.
One major lineage produces myeloid cells, including red blood cells, platelets, granulocytes, and monocytes.
Another major lineage produces lymphoid cells, including B lymphocytes, T lymphocytes, and natural killer cells.
Normal blood cell production depends on a balance between cell growth, maturation, and programmed cell death.
Leukemia develops when abnormal cells acquire changes that disturb this balance.
2. What Happens Inside the Body During Leukemia?
Leukemia begins when a blood-forming cell acquires genetic or molecular changes that give it an abnormal growth advantage.
These changes may affect genes that regulate cell division, maturation, survival, and DNA repair.
The abnormal cell may then multiply, producing a population of related cancer cells.
In many leukemias, the abnormal cells fail to mature properly. They may remain at an immature developmental stage and accumulate in the bone marrow.
These immature cells are often called blasts.
However, not every leukemia behaves in the same way. Chronic lymphocytic leukemia, for example, typically involves the accumulation of relatively mature-looking but abnormal lymphocytes.
As leukemia cells expand, they can disrupt the normal production of healthy blood cells.
This produces several important consequences.
First, reduced red blood cell production can cause anemia.
Second, reduced production of healthy white blood cells can increase susceptibility to infections.
Third, reduced platelet production can lead to bleeding and bruising.
Fourth, leukemia cells may accumulate in organs and tissues, causing enlargement of the spleen or liver, swollen lymph nodes, bone discomfort, or other symptoms.
In some patients, the total white blood cell count becomes extremely high. This can occasionally interfere with normal blood flow, particularly in certain acute leukemias. The resulting condition is called leukostasis and requires emergency treatment.
The clinical effects depend on the type of leukemia, the number and characteristics of abnormal cells, and how quickly the disease develops.
3. Major Types of Leukemia
Leukemia is classified according to the cell lineage involved and the speed or pattern of disease progression.
The four major categories are acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, and chronic myeloid leukemia.
A. Acute Lymphoblastic Leukemia
Acute lymphoblastic leukemia, commonly abbreviated as ALL, is a cancer involving immature lymphoid cells.
These abnormal cells multiply rapidly and interfere with normal blood cell production.
ALL is the most common type of cancer in children, although it can also occur in adolescents and adults.
The disease may involve B-cell precursors or T-cell precursors, producing B-ALL or T-ALL.
B-ALL is more common overall. T-ALL may be associated with enlargement of the thymus or a mass in the chest, which can cause coughing, breathing difficulties, or pressure symptoms.
Common symptoms include fever, fatigue, pallor, bruising, bleeding, bone pain, and recurrent infections.
Some patients develop enlarged lymph nodes, an enlarged liver or spleen, or involvement of the central nervous system.
Treatment usually involves several phases of chemotherapy and, in selected cases, targeted therapy, immunotherapy, or stem cell transplantation.
The prognosis depends on age, genetic features, initial disease characteristics, and response to treatment.
Many children with ALL achieve long-term remission, and a substantial proportion are cured. Outcomes in adults vary more widely and depend on the disease subtype and treatment response.
B. Acute Myeloid Leukemia
Acute myeloid leukemia, or AML, is a cancer involving abnormal myeloid blood-forming cells.
The disease often develops rapidly and can interfere with the production of red blood cells, normal white blood cells, and platelets.
AML occurs mainly in adults and becomes more common with increasing age, although it can occur in children and younger adults.
Patients may develop fatigue, fever, recurrent infections, easy bruising, gum bleeding, nosebleeds, or bone discomfort.
Some AML subtypes produce abnormal coagulation, creating a serious risk of bleeding or blood clots.
One particularly important subtype is acute promyelocytic leukemia, or APL. It is associated with a characteristic genetic rearrangement and can cause life-threatening bleeding abnormalities.
APL is a medical emergency because serious clotting and bleeding complications may occur early in the disease. Suspected APL requires immediate specialist assessment and prompt initiation of appropriate treatment.
AML treatment depends on the patient's age, fitness, genetic findings, and risk category. Options include intensive chemotherapy, lower-intensity regimens, targeted medicines, and stem cell transplantation in selected patients.
Modern molecular testing is particularly important because certain genetic changes help determine which treatments are most likely to be effective.
C. Chronic Lymphocytic Leukemia
Chronic lymphocytic leukemia, or CLL, is a cancer involving abnormal mature-looking B lymphocytes.
It mainly affects older adults and often develops slowly.
Many patients have no symptoms when the condition is discovered. A routine blood test may reveal a persistently elevated lymphocyte count.
Other patients develop enlarged lymph nodes, fatigue, recurrent infections, an enlarged spleen, or symptoms caused by anemia and low platelet counts.
CLL can impair normal immune function even when the patient has a high number of lymphocytes.
Some patients remain stable for many years without requiring treatment.
When treatment becomes necessary, options may include targeted medicines that affect B-cell signaling pathways or BCL-2, and selected antibody-based therapies.
Traditional chemotherapy is used less frequently than in the past for many patients because effective targeted treatments are available.
The choice of treatment depends on disease activity, genetic characteristics, symptoms, other health conditions, and patient preferences.
D. Chronic Myeloid Leukemia
Chronic myeloid leukemia, or CML, is a cancer of myeloid blood-forming cells.
Most cases are associated with a genetic abnormality known as the Philadelphia chromosome, which results from a rearrangement between chromosomes 9 and 22.
This rearrangement creates the BCR::ABL1 fusion gene.
The resulting abnormal protein has increased tyrosine kinase activity, which promotes uncontrolled cell growth.
CML often develops gradually and may initially cause no symptoms.
Possible findings include fatigue, weight loss, night sweats, abdominal fullness, and enlargement of the spleen. A blood test may reveal an elevated white blood cell count.
The development of tyrosine kinase inhibitors has transformed CML treatment.
Medicines such as imatinib, dasatinib, nilotinib, bosutinib, and asciminib may be used in appropriate clinical settings.
These medicines target the abnormal signaling mechanism that drives the disease.
Many patients now achieve prolonged disease control and have life expectancies approaching those of people without CML, although individual outcomes vary.
E. Other Less Common Leukemias
Several less common disorders are classified within the broader family of leukemias.
These include hairy cell leukemia, adult T-cell leukemia/lymphoma, and certain forms of acute leukemia with distinctive genetic features.
Hairy cell leukemia is a rare B-cell malignancy that may cause low blood counts, an enlarged spleen, and increased susceptibility to infection.
Some rare leukemias require specialized treatment approaches based on their molecular characteristics.
Accurate classification is important because treatments that work well for one leukemia may not be appropriate for another.
4. Acute Versus Chronic Leukemia
The distinction between acute and chronic leukemia is important because it affects the urgency of evaluation and the treatment strategy.
Acute Leukemia
Acute leukemia generally involves immature blood cells that accumulate rapidly.
Symptoms may develop over days or weeks, although the timing varies.
Patients may experience significant fatigue, fever, bleeding, bruising, or infections because normal blood cell production becomes impaired.
Acute leukemia usually requires prompt specialist assessment and treatment.
Without appropriate treatment, some forms can progress rapidly and become life-threatening.
Chronic Leukemia
Chronic leukemia usually involves cells that appear more mature, although they are still abnormal.
The disease often develops more gradually.
Some patients have few symptoms and are diagnosed during routine blood testing.
Treatment may not be necessary immediately in every chronic leukemia. For example, selected patients with early-stage CLL can be monitored until there is evidence that treatment is needed.
However, chronic does not mean harmless. Some chronic leukemias can cause significant complications or progress to a more aggressive phase.
The decision to treat depends on the particular leukemia, symptoms, blood counts, molecular findings, and evidence of disease progression.
5. Causes of Leukemia
The exact cause of leukemia is not known in most patients.
Leukemia develops through changes in the genetic material of blood-forming cells. These changes may alter how cells grow, mature, survive, and respond to signals.
Some genetic abnormalities arise during a person's lifetime, while others may be associated with inherited susceptibility.
In most cases, it is not possible to identify one event that directly caused the disease.
Genetic Mutations
Genes provide instructions for the production and regulation of proteins.
When important genes acquire mutations or other abnormalities, the affected cell may gain a growth advantage.
Some changes activate pathways that promote cell division. Others interfere with normal cell maturation or the mechanisms that eliminate damaged cells.
Leukemia often involves multiple genetic changes rather than one isolated mutation.
Chromosomal Abnormalities
Chromosomes contain the body's genetic material.
Certain leukemias are associated with specific chromosomal rearrangements, deletions, or changes in chromosome number.
For example, the BCR::ABL1 fusion gene is a defining feature of most cases of CML.
Other genetic abnormalities help classify acute leukemias and predict how they may respond to treatment.
Inherited Susceptibility
Some inherited genetic conditions increase the risk of leukemia.
Examples include Down syndrome and certain inherited bone marrow failure or cancer predisposition syndromes.
However, most people who develop leukemia do not have a recognized inherited syndrome.
Having a relative with leukemia does not mean that another family member will necessarily develop the disease.
Environmental Exposures
Certain environmental exposures have been associated with an increased risk of specific leukemias.
Examples include high doses of ionizing radiation and substantial exposure to benzene.
The degree of risk depends on the exposure, duration, dose, and other factors.
Most everyday environmental exposures have not been established as direct causes of leukemia.
Previous Cancer Treatment
Certain chemotherapy drugs and radiation treatments can increase the risk of developing a secondary leukemia years later.
These cases are sometimes called therapy-related myeloid neoplasms.
Although the risk is important, it must be considered in the context of the benefits of the original cancer treatment.
Smoking
Smoking is associated with an increased risk of AML and several other cancers.
Avoiding tobacco is an important way to reduce preventable cancer risks.
However, smoking does not explain every case of AML, and many people with leukemia have never smoked.
Viral Infections
Certain viruses are associated with specific lymphoid malignancies.
For example, human T-cell leukemia virus type 1 can cause adult T-cell leukemia/lymphoma in a minority of infected individuals.
However, most leukemias are not caused by a conventional contagious infection, and leukemia cannot generally be transmitted through ordinary contact.
Factors That Have Not Been Proven to Cause Leukemia
Leukemia is not caused by ordinary emotional stress, routine physical activity, or a single episode of eating a particular food.
It is also important not to assume that every person with leukemia has done something to cause the disease.
In many cases, the relevant genetic changes arise without an identifiable preventable trigger.
6. Risk Factors for Leukemia
Risk factors vary according to the leukemia subtype.
They increase the likelihood of developing a disease but do not guarantee that it will occur.
Important risk factors may include:
- Increasing age for several leukemia subtypes.
- Certain inherited genetic conditions.
- A family history of particular blood cancers.
- Previous chemotherapy or radiation therapy.
- Significant exposure to ionizing radiation.
- Exposure to benzene.
- Smoking, particularly in relation to AML.
- Certain uncommon viral infections associated with specific malignancies.
- Previous bone marrow disorders in selected cases.
Many patients have no identifiable risk factor.
Because leukemia has multiple causes and biological pathways, there is no single screening test or lifestyle measure that can prevent all forms of the disease.
7. Signs and Symptoms of Leukemia
The symptoms of leukemia vary according to the type, disease stage, and degree of bone marrow involvement.
Some symptoms develop because normal blood cell production is reduced. Others occur because leukemia cells accumulate in organs or tissues.
The following are important warning signs.
A. Persistent Fatigue
Fatigue is one of the most common symptoms.
When leukemia interferes with red blood cell production, anemia may develop. Reduced hemoglobin limits the amount of oxygen transported to body tissues.
Patients may feel exhausted even after adequate sleep.
Routine activities such as walking, climbing stairs, studying, or working may become difficult.
Fatigue has many possible causes and does not automatically indicate leukemia. However, persistent unexplained fatigue, especially when combined with other warning signs, should be evaluated.
B. Pale Skin
Anemia can cause the skin, lips, or inner eyelids to appear paler than usual.
The degree of pallor depends on the severity of anemia and the person's natural skin color.
Pallor may occur alongside weakness, dizziness, and shortness of breath.
C. Frequent or Persistent Infections
Leukemia can reduce the production of normal, functional white blood cells.
Neutropenia, which means a low neutrophil count, can increase the risk of serious bacterial and fungal infections.
Some patients develop recurrent infections, while others experience a single severe infection.
Fever may be the only early sign of infection in a patient with a very low neutrophil count.
In patients receiving leukemia treatment, fever can require immediate medical assessment because infection may progress rapidly.
D. Fever
Fever may develop because of infection or the inflammatory effects of the disease.
It can occur in acute and chronic leukemias.
However, fever is common in many illnesses and is not specific to cancer.
Persistent fever without an obvious explanation deserves medical evaluation, particularly if it occurs alongside unexplained bruising, weight loss, or severe fatigue.
E. Easy Bruising
A low platelet count can cause bruises to develop after minor injuries or without a clear explanation.
Patients may notice larger or more frequent bruises than usual.
The bruises may occur on the arms, legs, trunk, or other parts of the body.
Easy bruising can also result from medications, nutritional problems, liver disease, and other blood disorders.
Persistent unexplained bruising should not be ignored.
F. Bleeding From the Nose or Gums
Thrombocytopenia can cause nosebleeds, gum bleeding, and prolonged bleeding after minor cuts.
Some patients notice bleeding when brushing their teeth.
Women may experience unusually heavy menstrual bleeding.
Severe or persistent bleeding requires prompt medical attention.
G. Petechiae
Petechiae are tiny red, purple, or brown spots that occur when small amounts of blood leak from tiny blood vessels into the skin.
They may appear on the legs, arms, trunk, or inside the mouth.
Unlike many ordinary rashes, petechiae generally do not fade when pressure is applied.
They can occur in several conditions, including low platelet counts.
A sudden unexplained appearance of widespread petechiae, particularly with fever or bleeding, requires urgent medical assessment.
H. Bone and Joint Pain
Leukemia cells can accumulate in the bone marrow and increase pressure within the bone.
This may cause persistent bone pain, tenderness, or joint discomfort.
Children may limp, refuse to walk, or complain of pain in the legs.
Bone pain can have many causes, but unexplained persistent pain combined with fatigue, bruising, or fever warrants evaluation.
I. Enlarged Lymph Nodes
Lymph nodes are small structures that help filter lymphatic fluid and support immune function.
Leukemia cells may accumulate in lymph nodes, causing them to enlarge.
Patients may notice lumps in the neck, armpits, or groin.
Enlarged lymph nodes are more characteristic of some leukemia subtypes than others.
Many enlarged lymph nodes are caused by infections, but persistent, progressively enlarging, or unexplained nodes should be examined by a healthcare professional.
J. Enlarged Spleen
The spleen helps filter blood and supports immune function.
Certain leukemias cause the spleen to enlarge.
An enlarged spleen may produce fullness or discomfort in the upper left abdomen.
Some patients feel full after eating only a small amount because the enlarged spleen presses against the stomach.
Severe or sudden left upper abdominal pain, especially with dizziness or collapse, requires emergency assessment.
K. Enlarged Liver
Leukemia cells may infiltrate the liver, causing enlargement.
Patients may experience upper abdominal discomfort or fullness.
Liver enlargement may be identified during a physical examination or imaging.
It is not specific to leukemia and can occur in many other conditions.
L. Unexplained Weight Loss
Unintentional weight loss can occur when cancer changes the body's metabolism, reduces appetite, or causes persistent illness.
Patients may lose weight despite making no intentional changes to their diet or physical activity.
Weight loss becomes more concerning when accompanied by night sweats, fever, enlarged lymph nodes, or abnormal blood counts.
M. Night Sweats
Some patients experience heavy sweating during sleep.
They may wake with damp clothing or bedding even when the room is not particularly warm.
Night sweats can occur in leukemia and other illnesses, but they also have many noncancerous causes.
Persistent drenching night sweats, especially when associated with weight loss or fever, should be evaluated.
N. Shortness of Breath
Anemia may reduce the blood's ability to transport oxygen, causing breathlessness during physical activity.
In severe cases, patients may experience shortness of breath even at rest.
A large mass in the chest associated with certain leukemias can also interfere with breathing.
Sudden or severe breathing difficulty requires emergency care.
O. Abdominal Swelling
An enlarged spleen or liver may cause abdominal fullness or swelling.
In some patients, the abdomen becomes uncomfortable after eating.
Abdominal swelling can also arise from many unrelated conditions and requires assessment when persistent or unexplained.
P. Headaches and Neurological Symptoms
Rarely, leukemia may affect the central nervous system or cause complications related to blood cell abnormalities.
Symptoms may include persistent headaches, vomiting, visual disturbances, confusion, or other neurological changes.
Some symptoms can indicate serious conditions such as bleeding, infection, or leukostasis.
Sudden severe headache, confusion, weakness, seizures, or visual loss requires emergency assessment.
Q. Gum Swelling
Certain AML subtypes may infiltrate the gums and other tissues.
The gums may become swollen, tender, or prone to bleeding.
Gum swelling can also occur with dental infections and other disorders, so it requires appropriate evaluation.
R. Skin Changes
Leukemia can sometimes affect the skin.
Possible findings include unexplained bruising, petechiae, or less commonly, raised lesions caused by the infiltration of leukemia cells.
Some patients develop rashes related to infection, medication, or other conditions.
A skin change alone cannot establish a diagnosis of leukemia.
S. No Symptoms at All
Some chronic leukemias cause few or no symptoms during their early stages.
The disease may be discovered when a routine blood test shows an abnormal white blood cell count.
This is one reason why leukemia can sometimes be diagnosed before a person feels unwell.
However, routine blood testing is not recommended as a universal leukemia screening test for every healthy person without symptoms or specific indications.
8. Symptoms in Children Versus Adults
Leukemia can affect people of all ages, but its presentation may differ between children and adults.
Symptoms in Children
Children with leukemia may develop:
- Persistent fatigue or reduced activity.
- Pallor and weakness.
- Fever or recurrent infections.
- Easy bruising or nosebleeds.
- Bone or joint pain.
- Poor appetite and weight loss.
- Enlarged lymph nodes.
- Abdominal fullness caused by an enlarged liver or spleen.
- Unexplained changes in walking or willingness to play.
Young children may not be able to describe their symptoms clearly.
Parents may notice that a child becomes unusually tired, irritable, pale, or reluctant to participate in normal activities.
Because these symptoms overlap with common childhood illnesses, diagnosis requires medical evaluation and appropriate testing.
Symptoms in Adults
Adults may experience similar symptoms, including fatigue, infections, bruising, bleeding, fever, and weight loss.
Chronic leukemias may be discovered incidentally during routine blood testing.
Older adults may also have other medical conditions that complicate diagnosis and treatment decisions.
The presence of a symptom does not establish leukemia. The pattern, duration, examination findings, and blood test results all matter.
9. How Is Leukemia Diagnosed?
The diagnosis of leukemia involves several stages.
Doctors first assess the patient's symptoms and medical history. They then use blood tests, bone marrow studies, and specialized laboratory investigations to determine whether leukemia is present and identify the specific subtype.
Accurate classification is essential because treatment differs substantially among leukemias.
A. Medical History
The doctor asks about symptoms such as fatigue, fever, infections, bruising, bleeding, weight loss, and night sweats.
Questions may also cover the duration of symptoms, previous illnesses, medication use, occupational exposures, and family history.
The clinician may ask about previous chemotherapy or radiation treatment because these exposures can influence the assessment.
B. Physical Examination
The examination may include assessment for pallor, bruising, petechiae, swollen lymph nodes, and enlargement of the liver or spleen.
The doctor may also evaluate signs of infection, bleeding, dehydration, or neurological abnormalities.
A physical examination can identify important clues, but it cannot confirm leukemia by itself.
C. Complete Blood Count
A complete blood count, or CBC, measures red blood cells, hemoglobin, white blood cells, and platelets.
The results may reveal anemia, thrombocytopenia, an elevated white blood cell count, or a low white blood cell count.
Some patients have an unusually high number of white blood cells, while others have normal or low counts.
A CBC with a differential count provides information about the different types of white blood cells.
Abnormal results can suggest leukemia, but they can also occur in infections, nutritional deficiencies, medication effects, and other blood disorders.
D. Peripheral Blood Smear
A peripheral blood smear involves examining a stained sample of blood under a microscope.
A laboratory specialist evaluates the size, shape, and appearance of blood cells.
The smear may reveal immature cells called blasts or other abnormal features.
In some cases, the smear provides important clues about the type of leukemia.
However, not every patient with leukemia has obvious leukemia cells circulating in the blood.
E. Bone Marrow Aspiration
Bone marrow aspiration involves collecting a small sample of liquid marrow, usually from the pelvic bone.
The sample is examined to assess the number, appearance, and characteristics of developing blood cells.
It can help identify abnormal cell populations and determine the proportion of blasts.
The procedure is commonly performed using local anesthesia, although additional pain relief or sedation may be provided when appropriate.
Some pressure or discomfort may occur during aspiration.
F. Bone Marrow Biopsy
A bone marrow biopsy collects a small core of bone marrow tissue.
It allows examination of the structure of the marrow and the distribution of blood-forming cells.
Aspiration and biopsy provide complementary information.
Both may be needed to establish the diagnosis, although the exact approach depends on the suspected leukemia and the available blood and laboratory findings.
G. Flow Cytometry
Flow cytometry is a laboratory technique that identifies cell populations according to the proteins expressed on their surfaces or inside the cells.
These proteins are called markers.
The pattern of markers helps determine whether abnormal cells are lymphoid or myeloid and can distinguish among different leukemia subtypes.
Flow cytometry is particularly important in classifying acute leukemias and identifying certain lymphoid malignancies.
H. Cytogenetic Testing
Cytogenetic tests examine chromosomes for abnormalities in number or structure.
These tests can identify chromosomal changes associated with specific leukemia subtypes.
For example, detection of the Philadelphia chromosome or the associated BCR::ABL1 abnormality is central to the classification and management of CML.
Other chromosomal abnormalities can provide information about prognosis and treatment selection.
I. Molecular Genetic Testing
Molecular tests detect specific genetic changes within leukemia cells.
Depending on the suspected disease, testing may use techniques such as polymerase chain reaction, fluorescence in situ hybridization, or DNA sequencing.
These tests can identify mutations or fusion genes that help classify leukemia, predict response to treatment, and guide targeted therapy.
Molecular findings are particularly important in AML, ALL, and CML.
J. Lumbar Puncture
A lumbar puncture involves collecting a sample of cerebrospinal fluid from the lower back.
It may be performed when clinicians need to determine whether leukemia has affected the central nervous system.
The procedure is particularly relevant in selected patients with ALL and in other situations where central nervous system involvement is suspected or needs to be assessed.
The timing depends on the leukemia subtype, clinical circumstances, platelet count, and other safety considerations.
K. Imaging Studies
Imaging is not required to diagnose every leukemia.
However, ultrasound, CT, MRI, or other studies may be used to investigate enlarged organs, lymph nodes, chest masses, or suspected complications.
Imaging can help assess disease involvement and guide management.
L. Establishing the Final Diagnosis
The diagnosis is based on the combined findings from blood tests, morphology, flow cytometry, genetic studies, and, when indicated, bone marrow examination and other investigations.
The specialist identifies the precise leukemia subtype and evaluates its genetic risk characteristics.
This information helps determine the urgency of treatment, the most appropriate medicines, and whether stem cell transplantation or other advanced therapies should be considered.
10. Differential Diagnosis: Conditions That Can Resemble Leukemia
Several conditions can produce symptoms or blood test abnormalities similar to those seen in leukemia.
Viral Infections
Some viral infections can cause fever, fatigue, enlarged lymph nodes, and changes in white blood cell counts.
Certain infections may also cause temporary reductions in platelet counts.
Bacterial Infections
Severe bacterial infections can alter white blood cell counts and sometimes produce immature cells in the bloodstream.
The distinction between infection and leukemia may require repeat testing, blood smear examination, and additional investigations.
Aplastic Anemia
Aplastic anemia is a condition in which the bone marrow fails to produce sufficient blood cells.
Patients may develop anemia, infections, and bleeding.
Unlike leukemia, aplastic anemia does not involve the same uncontrolled accumulation of malignant blood cells.
Bone marrow examination helps distinguish the conditions.
Myelodysplastic Neoplasms
Myelodysplastic neoplasms are disorders in which blood cell production becomes abnormal and ineffective.
They may cause anemia, low platelet counts, or low white blood cell counts.
Some can progress to AML.
Bone marrow and genetic studies help establish the diagnosis.
Lymphoma
Lymphoma is a cancer of lymphocytes that usually develops in lymphatic tissues, although it can involve the bone marrow and bloodstream.
Some lymphomas overlap biologically with leukemia.
The distinction depends on the disease subtype, cell characteristics, and pattern of involvement.
Nutritional Deficiencies
Vitamin B12, folate, and iron deficiencies can cause abnormal blood counts.
Some deficiencies produce changes in blood cell size or appearance that may initially require further investigation.
Appropriate laboratory testing helps identify these conditions.
11. Staging and Risk Classification in Leukemia
Leukemia is not generally staged in the same way as solid tumors such as lung or breast cancer.
Instead, doctors use disease-specific classifications, risk groups, genetic findings, and treatment response to assess the likely course of the disease.
Acute Leukemia
For AML and ALL, important factors include the genetic characteristics of the leukemia cells, the patient's age and overall health, the initial blood findings, and the response to treatment.
Certain genetic abnormalities are associated with more favorable outcomes, while others may indicate a greater risk of relapse.
However, risk categories do not predict an individual outcome with absolute certainty.
Chronic Lymphocytic Leukemia
CLL may be classified using systems such as Rai or Binet staging.
These systems consider findings such as enlarged lymph nodes, enlarged organs, anemia, and low platelet counts.
Molecular markers, including TP53 abnormalities and immunoglobulin heavy-chain variable-region mutation status, can also influence treatment decisions.
Chronic Myeloid Leukemia
CML is commonly described in terms of chronic phase, accelerated features, and blast phase, although modern classification systems differ in terminology.
The chronic phase often responds well to targeted therapy.
Progression to a blast phase is more aggressive and requires a different treatment strategy.
The overall assessment depends on blood findings, molecular testing, and response to treatment.
12. Treatment of Leukemia: An Overview
Leukemia treatment aims to eliminate or control abnormal cells, restore healthy blood cell production, prevent complications, and prolong survival.
The treatment plan depends on the precise leukemia subtype.
A medicine that is highly effective for one leukemia may have little or no role in another.
Treatment decisions also depend on age, overall health, genetic findings, disease stage or phase, and the patient's goals.
Major treatment approaches include chemotherapy, targeted therapy, immunotherapy, stem cell transplantation, and supportive care.
Some patients require combinations of these approaches.
13. Chemotherapy
Chemotherapy uses medicines that damage cancer cells or interfere with their ability to divide and survive.
It remains an important treatment for several acute leukemias.
How Chemotherapy Works
Cancer cells often divide more rapidly or have altered survival mechanisms compared with many normal cells.
Chemotherapy exploits these differences, although it can also damage healthy cells that divide quickly.
These include cells in the bone marrow, hair follicles, and lining of the mouth and digestive tract.
As a result, chemotherapy can cause temporary reductions in blood counts, hair loss, mouth sores, nausea, diarrhea, and increased infection risk.
The exact side effects depend on the medicines used.
Induction Therapy
Induction therapy is designed to reduce the leukemia burden substantially and achieve remission.
In acute leukemia, this phase may involve intensive treatment over a relatively short period.
Patients often require close monitoring in hospital or specialist treatment centers.
Consolidation Therapy
After remission is achieved, additional treatment may be required to eliminate residual leukemia cells and reduce the risk of relapse.
This is known as consolidation therapy.
The medicines, intensity, and duration depend on the leukemia subtype and the patient's risk classification.
Maintenance Therapy
Some leukemias require prolonged lower-intensity treatment after the initial phases.
Maintenance therapy is particularly important in many treatment protocols for ALL.
It is not required in the same way for every leukemia.
High-Dose Chemotherapy
Certain patients receive high-dose chemotherapy as part of treatment or before stem cell transplantation.
Because high-dose treatment can severely suppress normal bone marrow function, careful supportive care is necessary.
14. Targeted Therapy
Targeted therapy uses medicines that act on specific proteins, mutations, or signaling pathways involved in cancer growth.
These treatments have transformed the management of several leukemias.
Tyrosine Kinase Inhibitors in CML
CML is driven by the BCR::ABL1 fusion protein in most cases.
Tyrosine kinase inhibitors block the abnormal signaling activity of this protein.
Examples include imatinib, dasatinib, nilotinib, and bosutinib. Asciminib works through a different mechanism involving the ABL myristoyl pocket.
These medicines can reduce leukemia cell numbers and achieve deep molecular responses in many patients.
Treatment generally requires ongoing monitoring of blood counts and BCR::ABL1 levels.
Some patients may eventually qualify for a supervised treatment-free remission attempt, but this is appropriate only for carefully selected individuals who meet specific criteria and can undergo frequent molecular monitoring.
Patients should never stop a CML medicine independently.
Targeted Therapy in AML
Some AML subtypes contain mutations that can be targeted by specific medicines.
For example, therapies directed against FLT3 or IDH1 and IDH2 mutations may be used in selected patients.
The availability and role of these medicines depend on the precise mutation, treatment setting, and local approvals.
Molecular testing helps identify whether a targeted treatment is appropriate.
Targeted Therapy in CLL
Several medicines used for CLL target B-cell receptor signaling or the BCL-2 protein.
Examples include BTK inhibitors such as acalabrutinib and zanubrutinib, and the BCL-2 inhibitor venetoclax.
These medicines can be highly effective in appropriately selected patients.
The choice depends on genetic features, kidney function, cardiovascular risk, other medications, treatment duration preferences, and other clinical considerations.
15. Immunotherapy
Immunotherapy uses or modifies immune mechanisms to recognize and attack cancer cells.
Several forms of immunotherapy are used in selected leukemias.
Monoclonal Antibodies
Monoclonal antibodies are laboratory-produced proteins designed to recognize particular targets.
Rituximab targets CD20 and may be used in selected B-cell malignancies.
Other antibodies target proteins expressed by particular leukemia cells.
Some antibodies directly affect cancer cells, while others recruit immune mechanisms to destroy them.
Bispecific Antibodies
Bispecific antibodies can bind to a cancer-associated target and a component of the immune system, bringing the two into close contact.
For example, blinatumomab targets CD19 on B-lineage leukemia cells and CD3 on T cells.
It is used in selected forms of B-cell ALL.
These medicines can produce important responses but may cause complications such as cytokine release syndrome or neurological toxicity.
CAR T-Cell Therapy
Chimeric antigen receptor T-cell therapy, or CAR T-cell therapy, involves collecting a patient's T cells and modifying them so they can recognize a specific cancer-associated target.
The modified cells are then returned to the patient.
Certain CAR T-cell products are used for selected forms of B-cell ALL and some other B-cell malignancies.
CAR T-cell therapy can produce deep and sometimes durable responses in appropriately selected patients.
However, it requires specialized facilities and can cause serious complications, including cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome.
Treatment must be delivered by experienced teams.
Immunotherapy in Acute Promyelocytic Leukemia
Acute promyelocytic leukemia is treated differently from many other forms of AML.
Treatment often involves all-trans retinoic acid, also called ATRA, and arsenic trioxide, with additional treatment determined by risk and clinical circumstances.
These therapies promote the maturation of abnormal promyelocytes and target the biology of the disease.
APL is highly treatable in many patients, but early bleeding and clotting complications can be life-threatening.
Suspected APL requires urgent specialist management.
.jpeg)
